Drugs / AB011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04400383 | Jun 2020 → Jul 2023 | gastric cancer, pancreatic adenocarcinoma | CARsgen Therapeutics Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-05-05 | CARsgen Therapeutics Co., Ltd. | Regulatory CARsgen’s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer carsgen.com ↗ |
| 2023-01-20 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI carsgen.com ↗
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a poster presentation highlighting the Phase 1 preliminary results of a recombinant humanized anti-claudin18.2 monoclonal antibody (AB011) , as monotherapy and combination therapy, for patients with advanced solid tumors was presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (“ASCO GI”), in San Francisco, California, during January 19-21, 2023. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-05 | CARsgen Therapeutics Co., Ltd. | CARsgen’s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer carsgen.com ↗ |
| 2023-01-31 | CARsgen Therapeutics Co., Ltd. | CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer carsgen.com ↗ |
| 2023-01-20 | CARsgen Therapeutics Co., Ltd. | CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI carsgen.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04400383 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-Claudin 18.2 monoclonal antibody injection” NCT04400383 ↗ |
| Target | CLDN18 | “recombinant humanized anti-CLDN 18.2 monoclonal antibody injection” NCT04400383 ↗ |